1. FDA. Information on Biosimilars. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ . Assessed 30 Nov 2017.
2. FDA. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf . Assessed 30 Nov 2017.
3. FDA. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf . Assessed Nov 30, 2017.
4. Dodds M, Chow V, Markus R, Pérez-Ruixo JJ, Shen D, Gibbs M. The use of Pharmacometrics to optimize biosimilar development. J Pharm Sci. 2013;102(11):3908–14. https://doi.org/10.1002/jps.23697 .
5. Dirks NL, Meibohm B. Population Pharmacokinetics Of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59. https://doi.org/10.2165/11535960-000000000-00000 .